当前位置:首页 > 关于我们 > 创投导师 > 谢良志

谢良志 | Xie Liangzhi


图片1.png

谢良志
麻省理工学院化学工程系博士,北京神州细胞生物技术集团股份公司、北京义翘神州科技股份有限公司创始人、董事长。
在麻省理工就学期间,谢博士首创化学计量控制的动物细胞高密度流加工艺技术,1994年在全球首次将抗体产量提高到2.4克/升,奠定了全球抗体和蛋白药物产业化的基础。1997年谢博士加入美国默克集团(Merck & Co Inc)从事疫苗工艺研究,参与了3个上市疫苗的研发,领导建立了全球人用活病毒疫苗规模最大、技术最先进的艾滋病疫苗工艺开发。
2002年谢博士回国创业,创办神州细胞公司,专门从事大分子生物药的研发工作;2007年创办义翘科技,从事科研生物试剂和生物技术服务。
谢博士担任的社会职务包括国家“新药创制”重大专项总体组专家、第十三届全国政协委员等。

Xie Liangzhi
Dr. of Department of chemical engineering, MIT; founder and chairman of Beijing SinoCellTech Group Co., Ltd. and Beijing Sino Biological Inc.
During his study at MIT, Dr. Xie pioneered stoichiometric control of high-density fed batch processing technology for animal cells. In 1994,  he raised the production of antibody to 2.4g/L for the first time in the world, which laid the foundation for the industrialization of antibody and protein drugs in the world. In 1997, Dr. Xie joined the Merck & Co Inc in the research of vaccine technology, participated in the research and development of 3 listed vaccines, and led the establishment of the largest and most technologically advanced AIDS vaccine technology development in the world.
In 2002, Dr. Xie returned to China to start a business and founded SinoCellTech, specializing in the research and development of macromolecular biological drugs; In 2007, Beijing Sino Biological Inc was founded, engaged in scientific research of biological reagents and biotechnology services.
Dr Xie held social positions including experts of the national major special group on "new drug creation" and members of the 13th CPPCC.

0.174566s